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adrenergic receptors inhibits contractility
and mediates NO-dependent
vasodilation. Tumor-draining lymphatics
have a denser innervation and increased
contractility, which can be diminished by
b2-adrenergic agonists.
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Lymphatic vessels (LVs) are important in the regula-
tion of tissue fluid homeostasis and the pathogenesis
of tumor progression. We investigated the innerva-
tion of LVs and the response to agonists and antago-
nists of the autonomic nervous system in vivo. While
skin-draining collecting LVs express muscarinic, a1-
and b2-adrenergic receptors on lymphatic endothe-
lial cells and smooth muscle cells, intestinal lacteals
express only b-adrenergic receptors and muscarinic
receptors on their smooth muscle cells. Quantitative
in vivo near-infrared imaging of the exposed flank-
collecting LV revealed that muscarinic and a1-adren-
ergic agonists increased LV contractility, whereas
activation of b2-adrenergic receptors inhibited
contractility and initiated nitric oxide (NO)-dependent
vasodilation. Tumor-draining LVs were expanded
and showed a higher innervation density and
contractility that was reduced by treatment with atro-
pine, phentolamine, and, most potently, isoproter-
enol. These findings likely have clinical implications
given the impact of lymphatic fluid drainage on intra-
tumoral fluid pressure and thus drug delivery.
INTRODUCTION
The lymphatic vascular system is responsible for tissue fluid ho-
meostasis, lipid absorption, and mediation of immune re-
sponses. It initiates as a network of blind-ended capillaries
throughout most organs of the body. These capillaries have
discontinuous tight junctions in order to take up free fluid and
solutes from the interstitium or lipids from the intestinal tract.
Antigen-presenting cells, as well as antigen itself, enter the
lymphatic system at the level of the capillaries before being con-
ducted into collecting lymphatic vessels (LVs). Concurrent with
an increasing diameter, collecting LVs are covered by a thin layerCell
This is an open access article under the CC BY-Nof smooth muscle cells that are required for the intrinsic contrac-
tility of lymphatic collectors (Gashev, 2008; Zawieja et al., 1993).
Together with intraluminal valves, their active contractions
ensure unidirectional lymph flow against an increasing pressure
gradient. Collecting LVs conduct lymph through one or more
lymph nodes until it ultimately reaches the bloodstream at the
subclavian veins.
The mechanisms regulating collecting LV contractility are not
entirely understood. Generally, there are both extrinsic and
intrinsic factors that influence lymph flow. Extrinsic factors
include the passive movement of lymph by contractions of stri-
atedmuscles (e.g., during walking), as well as by nearby arteries,
which through vasomotion can conduct their pulsation to LVs
(Gashev, 2008; Zawieja et al., 1993). With regard to intrinsic
mechanisms, mechanical parameters such as shear stress and
intraluminal pressure gradients within the LVs exert important in-
fluences on smooth muscle cell behavior (reviewed in Scallan
et al., 2016). Vasoregulatory factors, including nitric oxide (NO),
also have a strong influence on the contractility. NO is an effec-
tive vasodilator and has negative inotropic effects on LVs (Scal-
lan and Davis, 2013). The release of NO is induced by high shear
stress within the vessel (Kornuta et al., 2015; Kunert et al., 2015)
or by a variety of signaling molecules such as vascular endothe-
lial growth factor A (VEGF-A) (Lahdenranta et al., 2009). Surpris-
ingly, the potential regulation of LV contractility by the autonomic
nervous system has not received much attention thus far.
Nerves in close proximity to LVs have been described in hu-
mans (D’Andrea et al., 2013, 2015) and large animals, including
cows and dogs (Ohhashi et al., 1982; Todd and Bernard,
1973), and ex vivo studies have reported responses of the
contraction pattern of isolated LVs to several neurotransmitters
(McHale et al., 1980, 1990; Ohhashi and Azuma, 1986). However,
the results of these ex vivo studies are somewhat contradictory.
While previous studies consistently found activation of lymphatic
contractility by the a-adrenergic nervous system, some attrib-
uted these effects solely to the activation of a1 receptors (Benoit,
1997), whereas others reported that only a2 receptors, but not a1
receptors, are needed (Hashimoto et al., 1994). Similarly, con-
flicting results have been reported regarding the role of theReports 27, 3305–3314, June 11, 2019 ª 2019 The Author(s). 3305
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Neurotransmitter Receptors Are Expressed on LVs in an
Organ-Specific Manner
(A) qPCR-based detection of adrenergic b1 and b2 receptor (ADRB1 and
ADRB2) mRNA in two primary human LEC lines (shown as blue and blue-
striped columns). Expression was confirmed at the protein level using western
blots with human bronchial smooth muscle cells (hBSMCs) as a positive
control and the tumor cell line MeWo as a negative control.
(B, D, and F)Whole-mount staining of flank collector showing a1 (B), b2 (D), and
M2 (F) receptors expressed on CD31+ LECs and aSMA+ smooth muscle cells.
Asterisks indicate b2-positive CD31
+ blood vessels, and open arrowheads
indicate b2-positive adipocytes.
(C, E, and G) LYVE-1+ lacteals and their associated aSMA+ cells do not ex-
press a1 receptors (C), but the lacteals express b2 receptors (E, arrows), and
the associated smooth muscle cells express M2 receptors (G, arrows). The a1
3306 Cell Reports 27, 3305–3314, June 11, 2019muscarinic nervous system, since its agonist acetylcholine (ACh)
induced LV relaxation (Ferguson, 1992; Hashimoto et al., 1994;
Ohhashi and Takahashi, 1991) as well as contraction (Ohhashi
et al., 1978). Recently, ex vivo studies using human tissue found
a strong induction of LV contracting activity by the adrenergic
agonist norepinephrine (NE) and an inhibitory effect of the
muscarinic antagonist atropine (Telinius et al., 2010, 2014). Over-
all, most of the current knowledge about the interaction between
the autonomic nervous system and LV contractility stems from
ex vivo studies, while in vivo studies are still lacking (Choe
et al., 2015; Ono et al., 2000). Importantly, virtually nothing is
known about potentially different responses of LVs to neuro-
transmitters in pathological conditions such as chronic inflam-
mation and cancer, where LVs play major pathogenetic roles
(Christiansen and Detmar, 2011; Stacker et al., 2014).
In this study, we investigated in detail the role of the autonomic
nervous system in the regulation of LV function under physiolog-
ical and pathological conditions. To this end, we first studied the
presence of different subtypes of nerves on murine LVs and
analyzed the expression profile of neurotransmitter receptors
on lymphatic endothelial cells (LECs) in vitro and in situ. These
studies revealed organ-specific expression patterns that might
explain previously reported diverging effects of neurotransmit-
ters in different organs. We then applied quantitative in vivo
near-infrared imaging techniques to directly investigate the ef-
fects of a broad spectrum of agonists and antagonists of the
autonomic nervous system on the contraction frequency and
amplitude of collecting LVs under physiological conditions.
These investigations were accompanied by live Ca2+ imaging
studies in vitro and in vivo. Finally, we investigated the effects
of selected neurotransmitters on tumor-draining LVs. Our results
reveal that under physiological conditions, contractions of
collecting LVs are activated via a-adrenergic and muscarinic re-
ceptors, while they are inhibited via activation of b2-adrenergic
receptors. Importantly, we found that tumor-draining LVs ex-
hibited more active contractility and that this contraction activity
can be inhibited by distinct agonists and antagonists of the auto-
nomic nervous system.
RESULTS
Neurotransmitter Receptors Are Expressed on LVs in an
Organ-Specific Manner
We first investigated the mRNA expression levels of all known
adrenergic and muscarinic neurotransmitter receptors in five
different primary human dermal LEC lines. LECs specifically ex-
pressed b1- and b2-adrenergic receptors (Figure 1A shows two
cell lines, and Figure S1A the additional three lines). These find-
ings were confirmed at the protein level by western blot (Fig-
ure 1A), with human bronchial smooth muscle cells (hBSMCs)
serving as a positive control and the tumor cell line MeWo as
a negative control. In a next step, we investigated the neuro-
transmitter receptors expressed in mouse tissue. Whole-mountreceptor expressing enterocytes (Baglole et al., 2006) are clearly visible
(asterisk in C). Images were obtained using confocal microscopy.
Scale bars represent 50 mm (B, D, and F) and 25 mm (C, E, andG). Data in (A) are
presented as mean ± SD. See also Figure S1.
Figure 2. Nerves Are Closely Associated with LVs
(A) Lymphatic collectors of Prox1-GFP mice are closely associated with pan-
neural marker TuJ1+ nerves (arrows).
(B) Tyrosine hydroxylase (TH)+ sympathetic nerves run along lymphatic col-
lectors of Prox1-GFP mice and form synapses (synapsin I, zoom-in).
(C) Choline acetyltransferase (ChAT) GFP+ parasympathetic nerves, which
form synapses (synapsin I), accompany mesenteric collectors (zoom-in).
(D) Collectors other than mesenteric collectors show no ChAT+ innervation.
Synapsin I staining shows the presence of other types of nerves (zoom-in).
Images were obtained using confocal microscopy.
Scale bars, 50 mm. See also Figure S2.staining of the flank collecting LVs and lacteal villi in the small in-
testine was performed. Adrenergic a1 receptors were present on
CD31+ LECs as well as on the aSMA+ smooth muscle cells of theflank collector (Figure 1B). In contrast to the collecting LVs,
neither the intestinal LYVE-1+ lacteals nor their associated
smooth muscle cells (aSMA+) demonstrated expression of a1 re-
ceptors (Figure 1C). Interestingly, the mesenteric collecting LVs
lacked expression of a1 receptors (Figure S1F). Whole-mount
staining revealed no detectable expression of b1 receptors on
either type of LVs (Figures S1B and S1C), whereas the b2 recep-
tors were expressed on LECs of all vessel types, lacteals, the
flank, and mesenteric collectors (Figures 1D, 1E, and S1G).
b2-Receptor expression was also detected on smooth muscle
cells of the flank and mesenteric collecting LVs, but not on the
smooth muscle cells surrounding the lacteal.
Even though it was not detected at the RNA level in cultured
human LECs, we next performed whole-mount staining for the
muscarinic receptor M2. We found expression of M2 receptors
by smooth muscle cells of the flank and mesenteric collector
and of the lacteal villi, whereas the LECs themselves only
showed expression ofM2 receptors in the collecting vessels (Fig-
ures 1F, 1G, and S1H). As a second method, flow-cytometry
studies on freshly isolated flank collector LECs were performed
(Figures S1I and S1J). Thereby, we were able to confirm the
expression of a1 and b2 receptors. Additionally, but to a lower
extent than b2 receptors, we also detected positive expression
of b1 receptors. Due to the lack of a suitable antibody, we were
unable to assess M2 receptor expression using this approach.
Taken together, these findings reveal that LVs specifically ex-
press receptors in an organ-site-dependent manner that may
enable them to respond to neurotransmitters released from the
autonomic nervous system.
Nerves Are Closely Associated with LVs
In order to exert neural effects on LVs, the presence of synapses
formed by nerves is required, as these represent the source of
neurotransmitters. Whole-mount staining of collecting LVs from
different organ sites of Prox1-GFP mice for the pan-neural
marker TuJ1 detected nerves running along LVs (Figure 2A).
Tyrosine hydroxylase (TH)-positive sympathetic nerves were de-
tected, forming synapsin-I-positive synapses on lymphatic col-
lectors (Figure 2B). Parasympathetic nerves are characterized
by their expression of choline acetyltransferase (ChAT). We
therefore performed whole-mount staining of ChAT-GFP mice
in combination with synapsin I staining to detect synapses.
Mesenteric lymphatic collectors demonstrated innervation with
parasympathetic nerves (Figure 2C, zoom-in), whereas no
ChAT+ neural structures were detected on collectors at other
organ sites, such as the flank (Figure 2D).
Whole-mount staining showed a close proximity of nerves
(TuJ1+), distinguishable as either sympathetic (TH+) or parasym-
pathetic (ChAT+), with intestinal lacteals (Figures S2A–S2C).
Synapsin I staining revealed that the nerves adjacent to lacteals
also formed synapses (Figures S2D and S2E).
Overall, these results demonstrate that autonomic nerves of
different subtypes are present near LVs, indicating the possibility
of a direct influence on LV function.
LECs Are Direct Targets of Neurotransmitters
To evaluate if LECs might demonstrate downstream signaling in
response to neurotransmitters, we next investigated their Ca2+Cell Reports 27, 3305–3314, June 11, 2019 3307
Figure 3. LECs Are Direct Targets of Neurotransmitters In Vitro
(A) Visualization of the algorithm made for Ca2+ quantification. After enhancing the quality of each frame (image pre-processing), each cell is detected separately
and linked between consecutive frames in order to track it over the whole duration of the video (Cell Detection and Linking). For each tracked cell (Track), the
fluorescence intensity over time is computed. If the signal changes notoriously over time, an activation event is recorded (Event Detection). A detailed description
can be found in STAR Methods.
(B) Quantification of in vitroCa2+ imaging of human primary LECs using Fluo8H in response to different neural agonists. Each horizontal line of the bar represents a
tracked cell; only activated cells are shown in gray. Fluo8H intensity is shown in grayscale, proportional to intracellular Ca2+.
(C) Quantification of the percentage of cells reacting with an increase of Ca2+ upon treatment with different agonists. LCIS, live cell imaging solution; Iso,
isoproterenol; Prop, propranolol. **p% 0.01. Data in are presented as mean ± SD; n = average per well of cells. Individual cells can be seen Figure S3.
See also Figure S3.response in vitro as well as in vivo. This approach was chosen
because activation of most muscarinic receptors and some
adrenergic receptors leads to an increase of intracellular calcium
as a second messenger. In vitro imaging of human LECs using
Fluo8H was quantified with a self-written algorithm that is ex-
plained in STAR Methods and Figure 3A. We found that intracel-
lular Ca2+ was increased upon treatment with NE (1 mmol/L) or3308 Cell Reports 27, 3305–3314, June 11, 2019isoproterenol (10 mmol/L) (Figures 3B and S3). To evaluate the
specificity of this experiment, pretreatment of cells with an
antagonist was performed. Propranolol (100 mmol/L) strongly
inhibited the increase of intracellular Ca2+ induced by isoproter-
enol (Figure 3B). The quantification of the percentage of acti-
vated cells was in line with the visual quantification of Ca2+
activation (Figure 3C).
Figure 4. LECs Are Direct Targets of Neurotransmitters In Vivo
(A) Schematic overview of in vivoCa2+ imaging usingCx40 GCaMP2mice. The
flank collector was used for imaging. Ingl LN, inguinal lymph node; ROI, region
of interest.
(B) Representative example of GCaMP2 intensity (top) measurement while a
mixture of pegylated NIR dye and acetylcholine was infused into the inguinal
lymph node. At time of arrival of the dye (bottom), there is a visible peak of the
GCaMP2 expression (frame 50, blue line).
(C) The GCaMP2 signal intensity at time point of arrival of the dye in the imaged
section was normalized to the signal intensity before arrival of the dye.
Differences are shown as percent change of the baseline signal intensity. **p%
0.01. Data are presented as mean ± SD; n = 3 mice.For in vivo imaging,Cx40 GCaMP2 transgenic mice were used
(Tallini et al., 2007). These mice express the calcium indicator
GCaMP2 under control of the connexin 40 promoter and provide
a dynamic readout of GFP signal intensity that is proportional to
the intracellular calcium concentration. Connexin 40 is ex-
pressed in arterial endothelial cells and to a lesser degree in
LECs. In these mice, we infused 0.5 mL of 10 mmol/L 20 kDa
PEG-IRDye680 (P20D680) near-infrared (NIR) tracer (Proulx
et al., 2013) either alone or mixed with adrenergic or muscarinic
agonists into the inguinal lymph node (Figure 4A) and evaluated aregion of interest over the efferent collecting LV. The tracer was
used to define the time point when the infused agonist arrives in
the region of interest. Ca2+ fluxes in the LECs were analyzed by
measuring changes in the GFP intensity before arrival of the
tracer compared to the time point of arrival (Figure 4B). When
tracer alone was infused, the GFP intensity dropped due to the
volume-induced dilation of the collecting vessel (Figure 4C).
When the muscarinic agonist ACh (27.5 mmol/L) was infused
with the tracer, a clear transient spike in GFP intensity was
observed (Figure 4C). The same was observed for the b adren-
ergic agonist isoproterenol (10 mmol/L).
Together, these results indicate that LECs might represent
direct targets of neurotransmitters.
The Autonomic Nervous System Regulates Lymphatic
Contractility In Vivo
To investigate the regulation of LV contractility by the auto-
nomic nervous system in vivo, we used a previously described
method (Chong et al., 2016). In brief, after the infusion of
0.5 mL of the P20D680 NIR dye into the inguinal lymph node,
the flank collector becomes visible and contractile activity
can be imaged (Figure 5A). Over a period of 8 min, the fluores-
cent intensity of the tracer in the vessel is imaged, which
corresponds to diameter changes of the vessel (Figure 5B)
and enables quantification of the contractility using a custom-
made algorithm (Chong et al., 2016). After the first 2 min, a
topical treatment was applied. We quantified contraction fre-
quency, amplitude, and pumping score, which is the product
of frequency and amplitude, after treatment with a range
of muscarinic, a-adrenergic, and b-adrenergic agonists and
antagonists.
Comparing the post-treatment period (minutes 4–7) with the
pretreatment period (first 2min), potent effects of several agonist
and antagonists were found (Figures 5C–5E, S5C, and S5D).
There was a strong increase of contractile activity upon treat-
ment with themuscarinic agonist carbachol (2 mmol/L; amplitude
212.62% of pre-value; pumping score 317.67% of pre-value).
Conversely, antagonization of themuscarinic system by atropine
(100 nmol/L) reduced the contraction activity significantly (fre-
quency 57.63% of pre-value; pumping score 44.26% of pre-
value). For the adrenergic system, we detected reduced
contractility upon treatment with the unspecific b-adrenergic
agonist isoproterenol (10 mmol/L; frequency 45.1%of pre-value).
To determine if this effect was mediated by b1 or b2 receptors,
the specific b1 agonist denopamine and the specific b2 agonist
salbutamol (both at 1 mmol/L) were studied. Only salbutamol
induced an inhibitory effect (frequency 65.29% of pre-value),
indicating that the effect is predominantly mediated by b2 recep-
tors. Treatment with agonists at two additional concentrations
(0.1 and 10 mM) also showed no significant effect of the b1
agonist, while the higher concentration of the b2 agonist showed
a strong trend of reduced frequency (62.88% of pre-value) (Fig-
ure S5B). The unspecific b adrenergic antagonist propranolol
(10 mmol/L) exhibited a trend to activate the contraction activity
(frequency 115.07% of pre-value, amplitude 171.55% of pre-
value, pumping score 197.86% of pre-value). To ensure speci-
ficity of the b2 agonist, competitive blocking studies were per-
formed. After the exposed vessels were treated at t = 2 min,Cell Reports 27, 3305–3314, June 11, 2019 3309
Figure 5. The Autonomic Nervous System
Regulates Lymphatic Contractility In Vivo
(A) Schematic overview of in vivo imaging of flank
collector contractility.
(B) Representative example of measured NIR-dye
intensity in the flank collector over time; topical
treatment was done at time point 2 min.
(C–E) Effects of topical treatment with neural ag-
onists and antagonists on lymphatic contraction
frequency (C), amplitude (D), and pumping score
(E). Shown are the post-treatment values as a
percentage of pretreatment values for mice under
injection anesthesia (ketamine, xylazine, and
acepromazine).
(G–I) Same is shown for mice under isoflurane:
changes in frequency (G), amplitude (H) and
pumping score (I).
(F and J) Quantification of the tonic contraction of
the flank collector upon treatment with neural ag-
onists and antagonists under injection anesthesia
(F; ketamine, xylazine, acepromazine) and iso-
flurane (J).
(K and L) Isoproterenol-mediated phosphorylation
of eNOS, as assessed (K) and quantified (L) by
western blot. VEGF-A was used as positive con-
trol. The western blot shown is a representative
example of at least three independent experi-
ments.
*p < 0.05, **p % 0.01. Data are presented as
mean ± SD. (C–F) n = 8 vessels for PBS, and n = 6
vessels for all other treatments. (G–J) n = 4 vessels
per treatment. (K and L) n = 1. See also Figure S5.either PBS or the b2 antagonist were added at t = 4 min, and
the vessels’ post-treatment was assessed at t = 6–9 min. While
PBS treatment had no effect on the reduction of contractility,
treatment with the b2 antagonist neutralized the effect of
the initial b2 agonist, resulting in no change in contractility
(Figure S5A).3310 Cell Reports 27, 3305–3314, June 11, 2019The a-adrenergic system has been re-
ported to induce contractility in isolated
LVs (Ono et al., 2000; Telinius et al.,
2014). In line with these results, we found
a reduced contraction activity upon an-
tagonization of the a adrenergic system
using phentolamine (10 mmol/L; ampli-
tude 62.42% of pre-value; pumping
score 46.79% of pre-value; Figures 5D
and 5E). Phentolamine was dissolved in
DMSO, reaching a final DMSO concen-
tration of 0.01%. In previous studies, we
confirmed that this concentration of
DMSO had no effect on the contraction
activity (Chong et al., 2016). Surprisingly,
we could not detect any effect of the
a-adrenergic (and, with much lower affin-
ity, b-adrenergic) agonist NE. This lack of
response was most probably due to the
usage of the injection anesthesia (keta-
mine, xylazine, and acepromazine) thatcontained a agonists itself. To investigate this hypothesis, we
repeated the adrenergic treatments with mice under isoflurane
anesthesia (Figures 5G–5I and S6). We confirmed the inhibiting
effect of the a antagonist phentolamine (10 mmol/L; amplitude
19.87% of pre-value), while the DMSO control showed no signif-
icant effect. More importantly, we found a strong activating
Figure 6. Tumor-Draining Lymphatic Col-
lectors Contract More Actively
(A) Growth of intradermally injected B16F10
tumors was measured over time using a caliper
(n = 7 mice).
(B) Overview picture of the flank area in a naive (left)
and a tumor-bearing Prox1-GFP mouse (right). In
the vicinity of the flank collector (asterisk), addi-
tional lymphatic collectors were formed draining
the tumor.
(C) Compared to physiological LVs (left), tumor-
draining vessels show denser innervation, visual-
ized with the pan-neural marker TuJ1 (Prox1-GFP
staining, green; aSMA, yellow).
(D) Quantification of innervation density (nerve
length/vessel length).
(E) Tumor-draining LVs show higher baseline ac-
tivity than the respective vessels in non-tumor-
bearing mice with regard to frequency, amplitude,
and pumping score.
(F) Contractility of tumor-draining vessels can be
inhibited by atropine, phentolamine, and isopro-
terenol.
*p < 0.05, **p% 0.01, and ***p% 0.001. Scale bars
represent 500 mm (B) and 25 mm (C). Data repre-
sent mean ± SD, and dots in (D) and (E) represent
vessels. (F) n = 4 vessels per treatment. BV, blood
vessel. See also Figure S6.effect of NE (1 mmol/L; frequency 277.29% of pre-value), indi-
cating that the lack of effect in the previous experiments was
due to the choice of anesthesia. To investigate whether the re-
sults observed after treatment with other mediators might also
have been affected by the injection anesthesia, we next treated
collecting LVs in mice anesthetized with isoflurane with b adren-
ergic compounds. Isoproterenol (10 mmol/L) induced compara-
ble effects (frequency 10.32% of pre-value) and propranolol
(10 mmol/L) had only minor effects on the contractility (frequency
66.63% of pre-value) (Figures 5G–5I).
Overall, these in vivo experiments identified a strong impact of
neurotransmitters on the contraction activity of lymphatic collec-
tors in mice.
b-Adrenergic Stimulation Regulates LV Tone by eNOS
Phosphorylation
Besides the effects on phasic contractions, we next investigated
whether treatment with neurotransmitters might also mediate
changes in vessel tone, since previous studies indicated that
NE increases the vessel tone of lymphatic collectors from
various organ sites by inducing vasoconstriction (Dobbins,
1992; Ono et al., 2000; Takahashi et al., 1990). While mice under
injection anesthesia did not show any effect of NE on the vessel
tone (Figure 5F), in line with the lack of any response in phasic
contractions, the vessel tone was increased in mice under iso-
flurane anesthesia (Figure 5J). We observed a decrease in vesselCell Rtone (vasodilation) upon treatment with
isoproterenol, independent of the anes-
thesia regimen used. As a potential medi-
ator of vasodilation, we next investigated
the phosphorylation state of eNOS inLECs upon treatment with b-adrenergic agonists by western
blot and found an increased phosphorylation after treatment
with isoproterenol (Figures 5K and 5L). Thus, treatment with
isoproterenol may lead to increased NO production in LECs.
The released NO acts on the nearby smooth muscle cells, in-
duces their relaxation, and, therefore, leads to a dilation of the
collecting LV.
Tumor-Draining Lymphatic Collectors Contract More
Actively
B16F10 melanomas were grown in the flank skin of Prox-1 GFP
mice (Figure 6A).When tumors reached 12mm in one dimension,
tumor-draining LVs were imaged in vivo. As reported by many
studies (Padera et al., 2002; Skobe et al., 2001; Stacker et al.,
2014), we found that several LVs were expanded in the vicinity
of the flank collector, demonstrating the direct activating effect
of the tumor on the lymphatic vasculature (Figure 6B). TuJ1
staining of the affected vessels showed a denser innervation
(Figures 6C and 6D). In line with this finding, the tumor-draining
flank collectors had a higher baseline contraction activity (Fig-
ure 6E). Based on the results obtained under physiological
conditions, we next investigated whether treatment with distinct
neurotransmitters might inhibit the contractility of tumor-draining
LVs. Indeed, atropine, phentolamine, and, most potently, isopro-
terenol reduced the pumping score significantly (Figures 6F
and S6).eports 27, 3305–3314, June 11, 2019 3311
DISCUSSION
In this study, we provide the first comprehensive in vivo charac-
terization of the regulation of LV contractility by agonists and
antagonists of the autonomic nervous system. Our findings
reveal that both smooth muscle cells and endothelial cells of
LVs express distinct neurotransmitter receptors and that nerves
and synapses are in contact with these vessels. We identified
specific functions of the sympathetic and the parasympathetic
nervous system with regard to LV contraction and confirmed
the distinct activation of signaling in LECs by Ca2+ imaging
in vitro and in vivo. The studies of tumor-draining LVs revealed
their increased innervation and contraction activity and also
identified neurotransmitters that may inhibit the activity of tu-
mor-draining LVs.
In our investigation of the expression of neurotransmitter
receptors in LECs, we found that cultured human LECs only
express b-adrenergic receptors, whereas, in addition, both
a1-adrenergic and M2-muscarinic receptors were found on mu-
rine collecting LVs by whole-mount staining and flow-cytometry
analysis. The lack of expression of several of these receptors
in vitro might indicate a change of the expression profile of
LECs under the in vitro culture conditions, in agreement with pre-
vious studies (Amatschek et al., 2007; Wick et al., 2007). In addi-
tion, these differences might also represent vessel-type-specific
expression patterns, since the cultured human LECs were iso-
lated from the skin and might be more representative of LECs
originating from capillaries and not from collecting LVs. Consis-
tent with this concept, murine lacteal LECs, representing cells of
specialized intestinal lymphatic capillaries, also only express
b-adrenergic receptors. However, species-associated differ-
ences between humans and mice cannot be ruled out as well.
Confirmation for the differently expressed receptors in LECs
in vitro compared to the in vivo situation was obtained by the
Ca2+ imaging studies, since cultured cells only responded to b
agonists, whereas there was also a response to the muscarinic
agonist ACh in vivo.
Our finding of an organ-specific expression pattern of neuro-
transmitter receptors may provide an explanation for the previ-
ously reported discrepancies of NE effects on LV function.
While contractility was increased in ex vivo preparations of pe-
ripheral collecting LVs from different species (including human)
after exposure to NE (Dobbins, 1992; Ono et al., 2000; Takaha-
shi et al., 1990; Telinius et al., 2014), in agreement with our
in vivo studies in mice, a recent study reported a diminished
contraction activity of intestinal lacteals after NE treatment
(Choe et al., 2015). Our findings indicate that the opposing ef-
fects of the same adrenergic agonist can be explained by the
absence of a-adrenergic receptors on the lacteals. Thus, NE
(being an a-adrenergic agonist and, with much lower affinity,
also a b-adrenergic agonist) likely acts as a b agonist in lac-
teals, leading to reduced contractility, whereas it promotes
contractions in lymphatic collectors via the a-adrenergic recep-
tors. This organ-specific response to NE makes sense physio-
logically, since under systemic stress conditions, enhanced
return of peripheral lymph fluid together with reduced energy
expense for the gastrointestinal lipid transport might be
advantageous.3312 Cell Reports 27, 3305–3314, June 11, 2019A major conclusion from our studies is that muscarinic and
a-adrenergic agonists activate the contractility of collecting
LVs, whereas b2-adrenergic agonists reduce the contraction fre-
quency. The activating effect mediated by NE is in agreement
with previous ex vivo studies (Hashimoto et al., 1994; Igarashi
et al., 1998; McHale, 1992; McHale et al., 1980; Telinius et al.,
2014). However, whereas some of these studies indicated that
this effect is mediated via a2 receptors (Hashimoto et al.,
1994), others suggested that both a1 and a2 receptors are
involved (Igarashi et al., 1998). Our findings that there are pro-
found differences in the expression patterns of neurotransmitter
receptors on different types of LVs indicate that some of the re-
ported differences might relate to organ-specific responses to
neurotransmitters. In support of this concept, LVs isolated
from the liver and lungs of pigs showed decreased contraction
and were dilated upon ACh treatment (Ferguson, 1992; Hashi-
moto et al., 1994), similarly to isolated thoracic ducts of dogs
(Ohhashi and Takahashi, 1991). By contrast, in rat mesenteric
vessels (Fang et al., 2007), operation-induced vagotomy resulted
in a reduced contraction rate, indicating an activating role of the
parasympathetic nervous system with its main neurotransmitter,
ACh, in line with the contraction-inducing effects of ACh in
bovine mesenteric LVs (Ohhashi et al., 1978). Another possible
explanation for these opposing effects of ACh might be the ratio
of muscarinic receptors expressed on LECs versus smoothmus-
cle cells. If muscarinic receptors are expressed predominantly
on smooth muscle cells, then their activation likely induces LV
contraction, whereas binding of ACh on muscarinic receptors
on LECs induces NO release (Scallan and Davis, 2013), resulting
in vessel dilation and reduced contractility. Thus, a detailed char-
acterization of the neurotransmitter receptor expression profiles
of human LVs from different organs, as well as from model
organisms such as the mouse, is needed to better understand
the organ- and species-specific effects of the autonomic ner-
vous system.
Our data indicate that the choice of anesthesia is of great
importance for the design and interpretation of functional studies
of LV contractility. We were unable to detect the activating ef-
fects of the a-agonist NE when using an injection anesthesia
regimen that contained the a-agonist xylazine, thus masking
the effects of NE on LV contractility. By contrast, NE induced
an increased LV contraction frequency under isoflurane anes-
thesia. However, this anesthesia regimen turned out to be
associated with a general depression of LV contractions. Thus,
a thorough investigation of different anesthesia regimens for
functional in vivo studies of LVs would be helpful to ensure a
better cross comparison of published work.
The results of our in vivo studies are in agreement with the
improvement of secondary lymphedema after therapeutic inhibi-
tion of the sympathetic nervous system in patients after breast
cancer surgery (E. Choi et al., 2015) and gynecologic-cancer-
related surgery (Woo et al., 2013). In these clinical settings, the
treatment blocks the complete sympathetic nervous system
locally. Thus, one might speculate that the parasympathetic ner-
vous system, which is left intact after the treatment, promotes LV
contractions, resulting in improvement of the lymphedema.
One should keep in mind that the autonomic nervous system
influences both lymphatic and blood vessels, indicating that
therapies aimed at modulating blood vessel functions might also
impact the function of the lymphatic vascular system. As an
example, the long-term usage of b blockers for hypertension
might negatively influence the balanced system of physiological
lymphatic contractions. Similarly, while b2 agonists are success-
fully used to induce bronchodilation in asthma patients, they
might reduce the contractility of lymphatics of the lung and in-
crease NO release by LECs, potentially leading to a reduced fluid
clearance of the lung tissue.
To our knowledge, our studies identified for the first time that
the expanded tumor-draining LVs have a higher innervation
density, which might contribute to the observed increase in
contractility of the preexisting and newly formed LVs. The
increased contractility of tumor-draining LVs is in agreement
with a previous study in mice where increased smooth muscle
cell coverage was also detected (Gogineni et al., 2013).
Together, these findings reveal that tumors not only induce
LEC proliferation and lymphangiogenesis but also profoundly
change the anatomical structure and function of tumor-draining
LVs. Our findings that specific agonists and antagonists of the
autonomic nervous system reduce the contractility of tumor-
draining LVs might be of potential relevance for clinical cancer
therapy. In the future, targeted long-term treatment of tumor-
draining LVs would be needed to investigate whether the inhi-
bition of lymphatic contractility ultimately results in reduced tu-
mor growth and metastasis. At the same time, these studies
could also address possible negative effects of an increased
interstitial pressure induced by such long-term treatments,
including potentially reduced tumor tissue penetration of thera-
peutic compounds.STAR+METHODS
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Antibodies
alpha-1 adrenergic receptor Santa Cruz cat# sc-1477; RRID:AB_630854
beta-1 adrenergic receptor abcam cat# ab3442; RRID:AB_10890808
beta-2 adrenergic receptor abcam cat# ab13989; RRID:AB_300816
muscarinic acetylcholine receptor 2 abcam cat# ab109226; RRID:AB_10858602
muscarinic acetylcholine receptor 3 Santa Cruz cat# sc-9108; RRID:AB_2291779
Synapsin-1 Invitrogen cat# 51-5200; RRID:AB_87668
Tyrosine Hydroxylase R&D cat# AF7566
Tyrosine Hydroxylase Invitrogen cat# P21962; RRID:AB_2539844
III beta Tubulin BioLegend cat# 801201; RRID:AB_2313773
GFP Aves cat# GFP-1010; RRID:AB_2307313
CD31 BD Bioscience cat# 550274; RRID:AB_393571
alpha smooth muscle actin Sigma-Aldrich cat# C6198; RRID:AB_476856
LYVE-1 AngioBio cat# 11-034
LYVE-1 ReliaTech cat# 103-M130
eNOS ThermoFisher cat# PA1-037; RRID:AB_325774
Phospho-eNOS (Ser1177) CellSignaling cat# 9571; RRID:AB_329837
Tubulin Sigma-Aldrich cat# T9026V; RRID:AB_477593
goat Alexa 594 Invitrogen cat# A-11058; RRID:AB_2534105
rabbit Alexa 488 Invitrogen cat# A-21206; RRID:AB_2535792
rabbit Alexa 647 Invitrogen cat# A-31573; RRID:AB_2536183
chicken Alexa 488 Jackson ImmunoResearch cat# 703-545-1551
sheep Alexa 594 Invitrogen cat# A-11016; RRID:AB_2534083
rat Alexa 488 Invitrogen cat# A-21208; RRID:AB_2535794
rabbit HRP GE Healthcare cat# NA9340V; RRID:AB_772191
mouse HRP GE Healthcare cat# NA931; RRID:AB_772210
Chemicals, Peptides, and Recombinant Proteins
DL-Norepinephrine hydrochloride Sigma-aldrich cat# A7256
Phentolamine hydrochloride Sigma-aldrich cat# P7547
Atropine sulfate salt monohydrate Sigma-aldrich cat# A0257
Carbachol Millipore cat# 212385
()-Isoproterenol hydrochloride Sigma-aldrich cat# I6504
(±)-Propranolol hydrochloride Sigma-aldrich cat# P0884
R(-)-Denopamine Sigma-aldrich cat# D7815
(±)-Metoprolol (+)-tartrate salt Sigma-aldrich cat# M5391
Salbutamol Sigma-aldrich cat# S8260
ICI-118,551 hydrochloride Sigma-aldrich cat# I127
Experimental Models: Cell Lines
MeWo Sigma-Aldrich cat# 93082609
human bronchial smooth muscle cells ScienCell cat#3400
B16F10 ATCC CRL-6475, RRID:CVCL_0159
human dermal lymphatic endothelial cells Group Prof. Detmar N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
Prox-1 GFP Dr. Young-Kwon Hong, University of Southern
California
I. Choi et al., 2011
ChAT GFP Jackson Laboratories Strain No 007902
Cx40BAC-GCaMP2 Dr. Michael Kotlikoff, Cornell University and
the CHROMus mouse resource
R24HL120847
C57BL/6J Jackson Laboratories Strain No 000664
Oligonucleotides
See Table S4 for used primers N/A
Software and Algorithms
Quantification algorithms For full MATLAB codes please see STAR Methods. N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael
Detmar (michael.detmar@pharma.ethz.ch).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell culture
Primary male human LECs (Hirakawa et al., 2003) were cultured under standard culture conditions (37C and 5% CO2) on collagen
(Advanced BioMatrix) coated dishes (50 mg/mL) in EBM medium (Lonza) containing 20% FBS (GIBCO), 1% penicillin/streptomycin
(GIBCO), 2 mmol/L L-glutamine (GIBCO), 25 mmol/mL cAMP (Sigma-Aldrich) and 10 mg/mL hydrocortisone (Sigma-Aldrich).
Human bronchial smooth muscle cells were purchased from ScienCell and cultured under standard conditions in Smooth Muscle
Cell Medium 2 containing the Supplemental Mix (both PromoCell). MeWo cells (Sigma Aldrich) were cultured under standard culture
conditions in DMEM containing pyruvate (GIBCO) and 10% FBS.
Mice
Mice were group housed in IVC cages containing a mouse house and environmental enrichment under pathogen-free conditions.
Mice were not involved in previous procedures. Mice of both genders were used at the age of 7-20 weeks for organ collection
and 7-12 weeks for in vivo imaging. Prox1-GFP mice on the C57BL/6J background, used for clear visualization of LVs in whole
mounts and tumor studies, were a kind gift of Dr. Young-Kwon Hong, University of Southern California (Choi et al., 2011). B6.Cg-
Tg(RP23-268L19-EGFP)2Mik/J (ChAT-GFP, strain number 007902) mice and C57BL/6J mice were purchased from Jackson Labo-
ratories, Bar Harbor, ME.Cx40BAC-GCaMP2mice (Tallini et al., 2007) were obtained fromDr. Michael Kotlikoff, Cornell University and
the CHROMus mouse resource (R24HL120847).
For organ collection at the end of imaging, mice were euthanized with an overdose of anesthesia (160 mg/kg ketamine; 0.4 mg/kg
medetomidine) followed by cervical dislocation and opening of the chest cavity. All experiments were approved by Kantonales Vet-
erinaeramt Zurich (protocols: 11/2012, 12/2015).
METHOD DETAILS
LEC treatment in vitro
LECs were incubated in EBM containing 1% FBS overnight (starvation medium). Compounds of interest (Table S1) were added in
starvation medium. Antagonists were added 30min before treatment of the cells with the corresponding agonist. 15min after agonist
addition, total protein was extracted and protein concentration was measured using a Pierce BCA assay (ThermoFisher).
Western blotting
Equal amounts of denaturized protein were loaded per slot, using pre-cast NuPage gels (ThermoFisher). A Mini Gel Tank systemwas
used to run and blot the gels (ThermoFisher) according to manufacturer’s instructions. After blocking the membranes, protein was
detected using specific primary antibodies (Table S2) and HRP-conjugated secondary antibodies (Table S3). ECL was used for visu-
alization using an Agfa Curix Developer. Quantification of phosphorylation was performed using FIJI (Schindelin et al., 2012).e2 Cell Reports 27, 3305–3314.e1–e13, June 11, 2019
RNA isolation and qPCR
For RNA extraction, the NucleoSpin RNA kit fromMacherey-Nagel was used according to the manufacturer’s instructions. RNA was
reverse transcribed with the High Capacity cDNA kit (Applied Biosystems/ThermoFisher). qPCR analyses were done in triplicate us-
ing SYBRGreen (Roche) on a 7900 HT Fast Real-Time PCR System (Applied Biosystems). The following genes were analyzed:
ADRA1A, ADRA1B, ADRA1d, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, ChRM1, ChRM2, ChRM3, ChRM4 and
ChRM5 (for primers see Table S4). For normalization, GAPDH expression was analyzed.
Tissue digestion and FACS analysis
For FACS analysis of LECs, the flank collectors were dissected, minced, and digested in a collagenase solution [530 u/mL Collage-
nase II (Worthington), 0.744 u/mL Elastase (Worthington),5 u/mLDNase I (Roche)] for 70min at 37C. The digested tissuewas passed
through a cell strainer, washed and labeled with antibodies (see Tables S2 and S3) for 30 min at 4C, followed by incubation of sec-
ondary antibody for 30 min at 4C. Cells were stained for Zombie-NIR used for life/dead discrimination. After washing, cells were
resuspended in FACS buffer for acquisition. Data were acquired on a FACS ARIA (BD) and analyzed using FlowJo v10.2 software
(Treestar Inc.).
Imaging of flank collector contractions
The contractility of the flank collecting LV was analyzed as described (Chong et al., 2016). In brief, mice were anesthetized using a
combination of xylazine (20 mg/ kg, Rompun 2%, Provet), ketamine (100 mg/kg, Ketasol, Graeub) and acepromazine (3 mg/kg,
Prequillan, Arovet) or with isoflurane (2.5%, Attane, Provet). After loss of a detectable response to toe pinches, micewere fixed on
a silicone dish and the flank collector was exposed. Tissue was kept moist by applying warm PBS and mice were kept on a heating
pad during the imaging. Cannulation of the inguinal lymph node enabled a 0.5 mL infusion of 10 mmol/L P20D680 dye into the node and
thereby visualization of the flank collector. For infusion, a pump (PHD2000, Harvard Apparatus, Cambridge, MA) was used, con-
nected to a custom-made catheter using polyethylene PE-10 tubing (SCI, Lake Havasu City, AZ) and a 30-g needle. After stabilization
of the contractility, videos of 8 min (9 min for the specificity testing) duration were acquired. Local topical treatment of the flank col-
lector was done at time point 2 min (compound information see Table S1). For the specificity testing, the second treatment was topi-
cally added at time point 4 min. Videos were acquired using either a Zeiss StereoLumar.V12 stereomicroscope with AxioVision (Carl
Zeiss, Feldbach, Switzerland) software and a Photometrics Evolve 512 camera or a Zeiss AxioZoom.V16 fluorescence zoom micro-
scope with Zen Pro (Carl Zeiss) software and a QImaging OptiMOS sCMOS camera (QImaging, Surrey, Canada) in combination with
a light-emitting diode illumination system pE-4000 (CoolLED Ltd, Andover, UK) and filters for Cy5 (Carl Zeiss). The contractility was
quantified using a previously described algorithm (Chong et al., 2016).
Mice were allocated randomly to a specific treatment. Group size was evaluated after first pilot studies using power-analysis.
Exclusion criteria for an infused vessel were: complete coverage with fat or visible luminal obstruction of the vessel induced by
the infusion by e.g., blood coagulates.
In vivo Ca2+ imaging
Flank collectors ofCx40BAC-GCaMP2mice were exposed. Infusion of either 0.5 mL of 10 mmol/L P20D680 tracer or amixture of tracer
with agonists was performed into the inguinal lymph node. During infusion, a video of the flank collector was acquired using a custom
built 2-photon laser-scanning microscope. For quantification of a possible Ca2+ peak, mean intensity of the GCaMP2 signal was
measured over the vessel wall during the video (Figure 5A). Specific compounds were randomly allocated to mice.
In vitro Ca2+ imaging
The Fluo8H, AM (AAT Bioquest, cat-no. 21091) was used according to themanufacturer’s instructions. In brief, Fluo8H stock solution
(1.14mol/L) was prepared by adding 1.5%Pluronic and 2.4%DMSO in PBS. Cells were incubated in EBM containing 1%FBS for 4h,
Fluo8H 1:500 in starvation medium was added and cells were incubated for 30 min at 37C, followed by 10min at room temperature.
Cells were washed twice with Live Cell Imaging Solution (Molecular Probes). Imaging of cells was performed in Live Cell Imaging So-
lution; compounds were added in the same volume of live cell imaging solution as the cells were cultured in, using 2x treatment so-
lutions. Imaging was performed using a fluorescentmicroscope (Nikon Eclipse Ti-E, Tokyo, Japan) in combination with aHamamatsu
ORCA-Flash4.0 CCD camera (Hamamatsu, Japan). FITC fluorescence videos were acquired and quantified as stated below.
Whole mount stainings
Vessels or pieces of small intestine were dissected out of 7- to 20-week-old mice of either gender. The small intestine samples were
cut open longitudinally to give access to villi. Samples were fixed with 4% PFA for 2h at 4C or for 1h in 100%methanol at 4C. After
washing in PBS, tissueswere incubated in 0.2%BSA, 5%donkey serum, 0.1%Triton-X in PBS for 3h at 4C. Primary antibodies were
incubated over night at 4C. After washing in 0.1% Triton X in PBS, secondary antibodies were applied in 0.1% Triton X in PBS for
2h at room temperature or at 4C for the small intestine. After several washes in PBS, tissues were mounted using Vectashield
(Vector) for confocal imaging. The antibodies used are listed in Tables S2 and S3. Whole mount pictures were acquired using a
LSM 780 FCS confocal microscope and ZEN software (Zeiss, Jena, Germany) and processed with FIJI. Positive control stainingsCell Reports 27, 3305–3314.e1–e13, June 11, 2019 e3
for the neurotransmitter receptors are as follows: a1-positive enterocytes are visible in Figure 1C, b1-positive heart tissue is provided
in Figure S1D, b2-positive blood vessels are visible in Figure 1D and M2-positive liver tissue is provided in Figure S1E.
B16F10 melanoma studies
Male C57BL/6J mice of 7 weeks were bilaterally injected intradermally with 105 B16F10 tumor cells in the flank skin. Tumor growth
was monitored by size measurements using a caliper. When tumors reached 12 mm in one dimension, tumor-draining LVs were
imaged in vivo. Mice were randomly assigned to compound treatments.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of innervation
Overall length of nerves covering vessels was measured manually in FIJI and divided by the length of the LV.
Statistical analyses
All statistical analyses were performed using the GraphPad Prism 5 software. Data are shown as means ± SD, information on exact
value and representation of n can be found in the respective figure legends. For comparison of more than two groups, one-way
ANOVA with Bonferroni post-test was used for normally distributed data. For quantifications from in vivo flank imaging, a paired
two-tailed Student’s t test was used for normal distributed data. A Mann-Whitney test was used for the comparison of two groups
if the data was non-normal distributed, tested by a Shapiro-Wilk test. A p value of p < 0.05 was considered significant (p < 0.05 *,
p% 0.01 **, p% 0.001***).
DATA AND SOFTWARE AVAILABILITY
Quantification of low frequency contractions
Experiments performed with isoflurane resulted in a much lower contraction activity which could not be analyzed with the previously
developed algorithm (Chong et al., 2016). Therefore, a new algorithm was developed (Figure S4). In order to determine the charac-
teristics of the peaks (i.e., amplitudes and periodicity) of the measured fluorescence signal, a MATLAB (MathWorks Inc., Natick MA,
USA) function with a graphical user interface was developed that performs the signal processing in a semi-automatically manner. The
user selects the peaks ðaiÞ of the fluorescence signal manually and based on these selected values, the absolute amplitudes ðAabsj Þ,
relative amplitudes ðArelj Þ and the frequency ðFjÞ are then calculated automatically. These parameters were calculated according to
the formulas
Aabsj =
Mj  ai + 1  ; (1)Arelj = 100 3

Aabsj
.
Mj

; (2)Fj = 1

Pj; (3)
withMj the baseline value of each peak according toMj = ai + ðai +2  aiÞ=2 in case of ai + 2 > ai orMj = ai + 2 + ðai  ai +2Þ=2 in case
of ai + 2 < ai, and Pi the time-difference between the two peaks ai and ai +1 with the first peak assigned to i = 1 and the second to i = 2
(and so on). For a visualization of the mathematical nomenclature used, see Figure S4. The formulation ensures that the amplitude
and periodicity values are also calculated correctly in case the signal contains negative peaks, or a mixture of positive and negative
peaks.
MATLAB Code
function [Amplitude_abs, Amplitude_rel, Period, Frequency] = AnalyzePeaks_Ampl_Freq_v2(x,f_s)
% Function to analyze a time-series regarding the characteritics of the
% peaks (i.e., amplitudes, period)
% _________________________________________________________________________
% For Steven Proulx and Samia Bachmann, ETH.
% May 2017 j Felix Scholkmann j Version 2
%__________________________________________________________________________
% INPUT
% x: signal to analyze
% f_s: sampling frequency in Hz
% OUTPUTe4 Cell Reports 27, 3305–3314.e1–e13, June 11, 2019
% Amplitude_abs: absolute amplitude values (first value: median, second value: inter quantile range,
IQR)
% Amplitude_rel: relative amplitude values (first value: median, second value: inter quantile range,
IQR)
% Period: period values [in seconds] (first value: median, second value: inter quantile range, IQR)
% Frequency: frequency values [in 1/min] (first value: median, second value: inter quantile range, IQR)
% important:
% The input signal (x) must contain at least 3 peask (i.e., at least 9
% points needs to be selected from the signal). This is necessary to be
% able to calculate the period values.t= ½1 : lengthðxÞ:=f_s;
%% ________________________________________________________________________
close all
scrsz = get(0,’ScreenSize’); figure(‘Position’,[100 50 1300 850]);
set(gcf., ‘color’, ‘w’); set(gcf.,’defaultaxesfontsize’,12)
subplot(2,20,[1,3])
% Please insert here the path to the file ‘‘Points.png’’
currentFolder = pwd;
Path = strcat(currentFolder,’\Points.png’)
img = imread(Path);
image(img);
set(gca, ‘XTickLabelMode’, ‘Manual’)
set(gca, ‘XTick’, [])
set(gca, ‘YTickLabelMode’, ‘Manual’)
set(gca, ‘YTick’, [])
title (‘Definition’,’fontsize’,14)
fig = subplot(2,20,[6,20]);
plot(t,x,’linewidth’,2,’Color’,[0.3, 0.5, 1])
axis tight
ylabel(‘Intensity’); xlabel(‘Time [s]’)
title (‘- > Please select the points (\alpha_{i}, \alpha_{i+1}, \alpha_{i+2}, i = 1, 2, ., \it
{N})’,’fontsize’,14)
% Get the points from the figure
disp(‘/ Please select the points in the figure. The press ‘‘Enter’’’)
[x, y] = getpts(fig);
hold on
vline_red(x(2:3:end))
vline_black(x(1:3:end))
vline_black(x(3:3:end))
n = length(x);
% Calculate the amplitudes
j = 1;
for i = 1:3:n-2;if y(i+2) > y(i)
M(j) = (y(i+2)-y(i))/2 + y(i);
A_abs(j) = abs(M(j) - y(i+1));
A_rel(j) = 100 * (A_abs(j)/M(j));
j = j+1;
else
M(j) = (y(i)-y(i+2))/2 + y(i+2);
A_abs(j) = abs(M(j) - y(i+1));
A_rel(j) = 100 * (A_abs(j)/M(j));
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end
end
plot(x(2:3:end),M,’ob’)
plot(x(1:3:end),y(1:3:end),’ok’)
plot(x(3:3:end),y(3:3:end),’ok’)
plot(x(2:3:end),y(2:3:end),’or’)
% Calculate the periods
j = 1;
for i = 1:3:n-4;
P(j) = x(i+4)-x(i+1);
j = j+1;
end
F = (1./(P))*60; % Frequency [1/min]
subplot(2,20,[21:23])
bar(A_abs,’b’);
ylabel(‘Amplitude (A_{abs}) [absolute]’); xlabel(‘Peak number’)
title ({’Amplitude values’,’[absolute]’},’fontsize’,14)
xlim([0,length(A_abs)+1])
subplot(2,20,[25:27])
bar(A_rel,’b’);
ylabel(‘Amplitude (A_{rel}) [%]’); xlabel(‘Peak number’)
title ({’Amplitude values’,’[%]’},’fontsize’,14)
xlim([0,length(A_rel)+1])
subplot(2,20,[29:31])
bar(F,’r’);
ylabel(‘Frequency [1/min]’); xlabel(‘Peak number’)
title ({’Frequency values’,’[1/min]’},’fontsize’,14)
xlim([0,length(F)+1])
subplot(2,20,35:36)
errorbar(median(A_rel),iqr(A_rel)/2,’k’);
hold on
plot(median(A_rel),’k.’,’markersize’,30)
ylabel(‘Amplitude [%] (median +- IQR)’)
set(gca, ‘XTickLabelMode’, ‘Manual’)
set(gca, ‘XTick’, [])
title([‘A_{rel} = ’ num2str(median(A_rel)),’ (‘ num2str(iqr(A_rel)),’) %’]);
subplot(2,20,39:40)
errorbar(median(F),iqr(F)/2,’k’);
hold on
plot(median(F),’k.’,’markersize’,30)
ylabel(‘Frequency [1/min] (median +- IQR)’)
set(gca, ‘XTickLabelMode’, ‘Manual’)
set(gca, ‘XTick’, [])
title([‘F = ’ num2str(median(F)),’ (‘ num2str(iqr(F)),’) 1/min’]);
% Generate output data
Amplitude_abs = [median(A_abs), iqr(A_abs)];
Amplitude_rel = [median(A_rel), iqr(A_rel)];
Period = [median(P), iqr(P)];
Frequency = [median(F), iqr(F)];
Quantification of in vitro Ca2+ imaging
Pre-processing. An important step to restore images is denoising, which consists of reducing noise present in images but at the
same time preserving objects’ features such as edges, texture, etc. In this context, we have opted to use the Block-Matching and 3D
filtering (BM3D) method which has shown its denoising capabilities in different datasets by preserving finer image structures (Dabov
et al., 2007; Danielyan et al., 2014).
Cell Detection. Once the image has been pre-processed, the next step is to detect the foreground objects, i.e., cells. To do this, we
use the Otsu thresholding method (Otsu, 1979), however instead of using a single threshold value, we adopt a two-level threshold to
detect the nucleus and the cytoplasm as joint single objects.e6 Cell Reports 27, 3305–3314.e1–e13, June 11, 2019
After thresholding, small objects are further removed since they usually correspond to non-relevant objects, such as air-bubbles. In
addition, since some cells may spatially be close to each other, they can end up being merged after thresholding. To cope with this
issue, we use the Watershed Transform. More precisely, each segmented object is represented as a basin and the detected Water-
shed Lines with the distance transform are used to separate the objects.
Cell Linking. Cells are detected at each single frame separately. In order to analyze how a cell activates over time, the detected cells
are first linked together over time using the Kalman filter (Kalman, 1960).
The Kalman filter comprises two steps: prediction and update. In the prediction step, the Kalman filter predicts the current state of
the system, based on the past, through a dynamic model. In the update step, the status of the system is corrected based on the
observed variables. In our case, the assignment/linking of a given cell to a specific track is based on the area of overlap of the
segmented cells between consecutive frames. The Kalman Filter therefore seeks to maximize the area of overlap between cell de-
tections over time. To obtain more robust predictions at time t, our system averages the bounding-box of the detected cells over the
last four frames. To remove false positives such as air-bubbles, our system discards objects with large location changes over time.
Also, short tracks are discarded for further processing. In our case, we impose the constraint that tracks shall cover at least 75% of
the total length of the input video.
Event Detection. Our event detection module is versatile and besides detecting which cells got activated, it can also find out when
exactly a given activation starts and ends over time. The module starts first by smoothing the cell’s intensity signal (the cell-intensity
track) to reduce noise. Smoothing is donewith amoving average filter. Note that the smoothing step is optional and the raw signal can
be directly used if so desired.
Next, the cell signals are normalized to compensate for effects such as photobleaching and also to facilitate the detection of cell
activations in the subsequent steps. The normalization of a cells’ signal is done by computing the average intensity mi, of the detected
cell at the frames before the injection time tinj(see Equation 1).
mi =
1
tinj
Xt = tinj
t = 0
f

xti

(Equation 1)
where fð Þ is the mean intensity value of the collection of pixels xti belonging to the detected cell i at time t.
The computed mean value mi of cell i is used to normalize the signal by dividing it into the cell signal values at all later times (see
Equation 2).
bf ðxiÞ = 1
mi
f

xti

; t =

t = tinj + 1; :::; N
	
(Equation 2)
where bf is the normalized cells’ signal and N corresponds to the total number of frames. Figure S3B shows an example of cell signals
before (upper graph) and after normalization (lower graph). Detected activations above the threshold value (displayed as a black
dashed line) are shaded, see next section of details of the detection algorithm.
To detect cell-activations, the normalized cell signals are thresholded. More precisely, signal values larger than a threshold value
are considered as activations and values lower than the threshold are set to zero. We set this threshold value empirically to be 1.25.
Note that this value can be tuned, if more detections are targeted, one can increase this value. It is important though to set this value in
a conservative manner. An example of cell activation is displayed in yellow in the left graph of Figure S3C. The thresholding step is
applied for all cell signals, in such away that all activations can bemapped as an activationmap. In Figure S3C, each row represents a
single cell signal and itsmean-intensity pixel values are displayed for each frame along the x axis. After thresholding the cell signals on
the normalized cell signals (middle graph in Figure S3C), a binary activation map is obtained in which cell activations are displayed as
white stripes (right graph, Figure S3C). The signal valueswhere the cell did not activate are set to zero. In addition, to remove potential
false negatives, our method first fills short gaps inside an event and also prunes short cell activations to remove false positives. In our
experiments, both values were empirically set to five frames.
One important property of our method is that it detects where a cell activation starts and ends. This is done by computing the first
order derivative over the binary activated signal and by looking respectively for the indexes where the derivative is respectively pos-
itive or negative (i.e., +1 or 1).
MATLAB Code (2 parts)
function kalmanMultiObjectTracking(videoName)
% KalmanMultiObjectTracking: this function detects a set of cells and
% tracks them over time. Cell detection involves image pre-processing where
% the original video frames are enhanced, e.g., denoising. The cell
% detections are mapped into cell-tracks, i.e., a set of temporal
% bounding-boxes for each detected cell.
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% videoName, e.g., videoName = ‘hu_NE1uM_2.avi’;
%
% Output:
% tracksHist.mat MATLAB file containing the cell-tracks.
opts = getDefaultParameters(); %# reading configuration parameters.
pathInputVideo = fullfile(opts.videoPath, videoName);
digitStr = ‘%d-’;
strAllMotionDigits = repmat(digitStr, 1, numel(opts.motionNoise));
motionNoiseStr = sprintf(strAllMotionDigits(1:end-1),opts.motionNoise);
strAllInitErrorDigits = repmat(digitStr, 1, numel(opts.initialEstimateError));
initErrorStr = sprintf(strAllInitErrorDigits(1:end-1),opts.initialEstimateError);
paramsDir = sprintf(‘%s_LRate%2.2f_visi%2.2f_age%d_invib%d_initErr%s_motNoise%s_measNoise%d_
%s_cSze%d’,.Copts.motionModel, opts.learningRate, opts.trackVisibility, opts.ageThreshold,.
opts.invisibleForTooLong, initErrorStr, motionNoiseStr, opts.measurementNoise, opts.-
thresh.type, opts.cell.size);
[videosPath, inVideoname, ] = fileparts(pathInputVideo);
videoNameOutputTrackRGB = sprintf(‘%s_track_rgb.avi’, inVideoname);
videoNameOutputTrackProc = sprintf(‘%s_track_proc.avi’, inVideoname);
videoNameOutputTrackBW = sprintf(‘%s_track_bw.avi’, inVideoname);
videoNameOutputBW = sprintf(‘%s_bw.avi’, inVideoname);
tracksDir = fullfile(videosPath, ‘tracks_kalmann_sel’);
tracksDirVideo = fullfile(tracksDir, inVideoname, paramsDir);
opts.framesOrigDir = fullfile(tracksDir, inVideoname, ‘frames’);
opts.framesProcDir = fullfile(tracksDirVideo, ‘frameProc’);
opts.maskDir = fullfile(tracksDirVideo, ‘frameMasks’);
opts.maskDirTracks = fullfile(tracksDirVideo, ‘frameMasksTracks’);
opts.framesOrigTracksDir = fullfile(tracksDirVideo, ‘framesOrigTracks’);
opts.framesProcTracksDir = fullfile(tracksDirVideo, ‘framesProcTracks’);
opts.maskDirTracksAll = fullfile(tracksDirVideo, ‘frameMasksTracksAll’);
opts.framesOrigTracksDirAll = fullfile(tracksDirVideo, ‘framesOrigTracksAll’);
createVideoDirs(tracksDirVideo, opts); %# creating output directories
videoObjTrackRGB = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackRGB),
‘Uncompressed AVI’);
videoObjTrackProc = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackProc),
‘Uncompressed AVI’);
videoObjTrackBW = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackBW), ‘Uncompressed
AVI’);
videoObjBW = VideoWriter(fullfile(tracksDirVideo, videoNameOutputBW), ‘Uncompressed AVI’);
fprintf(‘video: %s\n’,(fullfile(tracksDirVideo, videoNameOutputTrackRGB)));
tracksObj = fullfile(tracksDirVideo, sprintf(‘%s.mat’, inVideoname));
obj = setupSystemObjects(pathInputVideo, opts);
tracks = initializeTracks(); %# Create an empty array of tracks.
tracksHist = initializeTracksHistory();
nextId = 1; % ID of the next track
noFrames = 0;
if exist(tracksObj, ‘file’)
%# Detect moving objects, and track them across video frames.
while isDone(obj.reader)ell RepnoFrames = noFrames + 1;
fprintf(‘# Processing frame: %d\n’, noFrames);
frame = readFrame(obj);
%# image pre-processing and per-frame cell detection.
[centroids, bboxes, mask, frameDen] = detectObjects(frame, opts);
%# predict cell location.
[tracks, tracksHist] = predictNewLocationsOfTracks(tracks, tracksHist, noFrames);
%# link cells over time.orts 27, 3305–3314.e1–e13, June 11, 2019
[assignments, unassignedTracks, unassignedDetections] =.
detectionToTrackAssignment(tracks, centroids, bboxes, opts);%# update existing cell-tracks.
[tracks, tracksHist] = updateAssignedTracks(tracks, tracksHist, assignments, centroids,
bboxes, noFrames);
[tracks, tracksHist] = updateUnassignedTracks(tracks, tracksHist, unassignedTracks);
%# delete short tracks.
[tracks, tracksHist] = deleteLostTracks(tracks, tracksHist, opts);
%# create new tracks.
[tracks, tracksHist, nextId] = createNewTracks(tracks, tracksHist, centroids, bboxes,
unassignedDetections, nextId, noFrames);
%# saving tracks to disk.
dumpTrackingResults(frame, mask, tracks, tracksHist, tracksDirVideo, videoObjTrackRGB,
videoObjTrackBW, videoObjBW, noFrames, opts);
end
opts.totNoFrames = noFrames;
tracksHist = updateEmptyTracks(tracksHist, opts); %# check empty tracks frames and reduce its
totalVisibleCount
save(tracksObj, ‘tracksHist’, ‘-v7.30); %# save to disk the detected tracks.
else
fprintf(‘# Loading tracks\n’);
tracksHist = load(tracksObj);
tracksHist = tracksHist.tracksHist;
reset(obj.reader);
while isDone(obj.reader)
frame = readFrame(obj);
noFrames = noFrames + 1;
end
fprintf(‘# No of. frames: %d\n’, noFrames);
end
opts.totNoFrames = noFrames;
if isfield(tracksHist, ‘numEmptyMask’)
tracksHist = updateEmptyTracks(tracksHist, opts);
end
open(videoObjTrackRGB); %# create RGB video with cell tracks.
open(videoObjTrackProc); %# create RGB video for cell tracks (segmented/cells + bounding boxes).
open(videoObjTrackBW); %# create BW video for cell tracks (segmented/detected cells + bounding
boxes).
open(videoObjBW);%# create BW video file for cell detections (segmented/detected cells as binarys
masks).
noFrames = 0;
for ff = 1:opts.totNoFrames
noFrames = noFrames + 1;
frameOrigFile = fullfile(opts.framesOrigDir, sprintf(‘frame_%05d.tif’, ff));
frameDenFile = fullfile(opts.framesProcDir, sprintf(‘frame_%05d.tif’, ff));
frameMaskFile = fullfile(opts.maskDir, sprintf(‘frame_%05d.tif’, ff));
fprintf(‘#Processing frame: %d\n’, noFrames);
if exist(frameOrigFile, ‘file’) && exist(frameDenFile, ‘file’) && exist(frameMaskFile, ‘file’)frameOrig = imread(frameOrigFile);
frameDen = imread(frameDenFile);
frameMask = imread(frameMaskFile);
%# storing into disk each frame overlayed with the cell-tracks.
saveTrackingResults(frameOrig, frameDen, frameMask, tracksHist, videoObjTrackRGB,
videoObjTrackProc, videoObjTrackBW, videoObjBW, ff, opts);
end
end
close(videoObjTrackRGB); %# closing videoFile.
close(videoObjTrackProc); %# closing videoFile.Cell Reports 27, 3305–3314.e1–e13, June 11, 2019 e9
e10close(videoObjTrackBW); %# closing videoFile.
close(videoObjBW); %# closing videoFile.
end
function tracksThresh2Activations(videoName)
% tracksThresh2Activations: given the extracted cell-tracks of a
% given video (linked cells over time), this function detects which of
% the cells got activated. For that purposes, the mean pixel intensity
% of a segmented cell is computed at each frame. If the mean pixel
% intensity value is higher than a threshold, then an activation is fired.
% The original intensity values can also be smoothed to remove noise and if
% the interval of the activation is too short, then a false-positive activation
% is detected.
%
% Input:
% videoName, e.g., videoName = ‘hu_NE1uM_2.avi’;
%
% Output:
% a set of figures are stored into disk, containing a
% matrix-representation of the activated cell-signals.
addpath(genpath(‘./3rd/overlay/’));
%# reading default parameters, e.g., location of detected cells frames.
opts = getDefaultParameters();
if isfield(opts, ‘endThreatment’)Copts.endThreatment = 10;
end
if isfield(opts, ‘signal’)
opts.signal = [];
end
if isfield(opts.signal, ‘Type’)
opts.signal.Type = ‘orig’;
end
%# smoothing type for the cell signal.
if isfield(opts.signal, ‘smoothType’)
opts.signal.smoothType = ‘box’; % ‘golay’, ‘gauss’, ‘box’
end
%# threshold value
if isfield(opts.signal, ‘threshVal’)
opts.signal.threshVal = 1.25;
end
%# minimum duration of cell-activation
if isfield(opts.signal, ‘pruneEventDuration’)
opts.signal.pruneEventDuration = 5;
end
if isfield(opts.signal, ‘fillGaps’)
opts.signal.fillGaps = true;
end
if isfield(opts.signal, ‘fillGapsSze’)
opts.signal.fillGapsSze = 5;
end
[videosPath, videoNameInput, ] = fileparts(videoName);
digitStr = ‘%d-’;
strAllMotionDigits = repmat(digitStr, 1, numel(opts.motionNoise));
motionNoiseStr = sprintf(strAllMotionDigits(1:end-1),opts.motionNoise);
strAllInitErrorDigits = repmat(digitStr, 1, numel(opts.initialEstimateError));
initErrorStr = sprintf(strAllInitErrorDigits(1:end-1),opts.initialEstimateError);
paramsDir = sprintf(‘%s_LRate%2.2f_visi%2.2f_age%d_invib%d_initErr%s_motNoise%s_measNoise%d_
%s_cSze%d’,.
opts.motionModel, opts.learningRate, opts.trackVisibility, opts.ageThreshold,.ell Reports 27, 3305–3314.e1–e13, June 11, 2019
opts.invisibleForTooLong, initErrorStr, motionNoiseStr, opts.measurementNoise,
opts.thresh.type, opts.cell.size);
%# creating subdirectories where resuls are going to be stored.
tracksDir = fullfile(videosPath, ‘tracks_paper’);
tracksDirVideo = fullfile(tracksDir, videoNameInput, paramsDir);
signalDir = fullfile(tracksDirVideo, ‘signal’);
signalThreshDir = fullfile(signalDir, ‘thresh’);
signalEventsDir = fullfile(signalDir, ‘events’);
if exist(signalEventsDir, ‘dir’), mkdir(signalEventsDir); end
tracksFile = fullfile(tracksDirVideo, ‘validTracksIdx.mat’);
validTracksIdx = load(tracksFile);
validTracksIdx = validTracksIdx.validTracksIdx;
%# loading detected cell-tracks
if strcmpi(opts.signal.Type, ‘orig’)
threshSubDir = fullfile(signalThreshDir, ‘origdata’);
signalMeanFile = fullfile(tracksDirVideo, ‘signalMean.mat’);
signalMean = load(signalMeanFile);
signalMean = signalMean.signalMean;
signalMean(validTracksIdx,:) = [];
signalArray = signalMean;
if exist(threshSubDir, ‘dir’), error(‘Unknown directory: %s\n’, threshSubDir); end
signalEventsDir = fullfile(signalEventsDir, ‘origdata’);
if exist(signalEventsDir, ‘dir’), mkdir(signalEventsDir); end
signalTypeStr = opts.signal.Type;
tracksIdx = find(validTracksIdx);
elseif strcmpi(opts.signal.Type, ‘smooth’)
fprintf(‘# Loading %s data\n’, opts.signal.smoothType);
signalSmoothFile = fullfile(signalDir, ‘smooth’, sprintf(‘tracksSummary_%s.mat’,
opts.signal.smoothType));
signalMeanSmooth = load(signalSmoothFile);
signalMeanSmooth = signalMeanSmooth.signalMeanSmooth;
signalMeanSmooth(validTracksIdx,:) = [];
signalArray = signalMeanSmooth;
threshSubDir = fullfile(signalThreshDir, opts.signal.smoothType);
if exist(threshSubDir, ‘dir’), error(‘Unknown directory: %s\n’, threshSubDir); end
signalEventsDir = fullfile(signalEventsDir, opts.signal.smoothType);
if exist(signalEventsDir, ‘dir’), mkdir(signalEventsDir); end
signalTypeStr = sprintf(‘%s-%s’, opts.signal.Type, opts.signal.smoothType);
tracksIdx = 1:size(signalArray,1);
else
error(‘Unkown type: %s’, opts.signal.Type);
end
signalArrayNormFilename = fullfile(threshSubDir, ‘signalNorm.mat’);
ifexist(signalArrayNormFilename, ‘file’), error(‘Unknown file: %s\n’, signalArrayNormFilename);
end
signalNorm = load(signalArrayNormFilename);
signalNorm = signalNorm.signalNorm;
%# thresholding for activation.
signalBinaryActivation = signalNorm > opts.signal.threshVal;
[noTracks, ] = size(signalBinaryActivation);
%# fill possible gaps in the cell-activations
if opts.signal.fillGaps > 0
filledSignal = signalBinaryActivation;
for ii = 1:noTracksfilledSignal(ii,:) = bwareaopen(filledSignal(ii,:), opts.signal.fillGapsSze);
end
signalBinaryActivation = filledSignal;
strFillGap = sprintf(‘fillSze%d’, opts.signal.fillGapsSze);Cell Reports 27, 3305–3314.e1–e13, June 11, 2019 e11
e12 Celse
strFillGap = sprintf(‘nofill’);
end
signalActivation = zeros(size(signalBinaryActivation));
if opts.signal.pruneEventDuration > 0
strPruneEvent = sprintf(‘pruned%d’, opts.signal.pruneEventDuration);
else
strPruneEvent = sprintf(‘noprune’);
end
%# analyzing cell-track duration.
stats = repmat(struct(‘startIdx’,[], ‘endIdx’, [], ‘duration’, [], ‘eventIdx’, [], ‘activation’,
0), noTracks, 1);
for tt = 1:noTracks
trackActivation = signalBinaryActivation(tt,:);
trackActivation = diff([0 trackActivation 0]);
eventStartIdx = find(trackActivation > 0);
eventEndIdx = find(trackActivation < 0)-1;
eventDuration = eventEndIdx - eventStartIdx + 1;
if opts.signal.pruneEventDurationstringIdx = (eventDuration > = opts.signal.pruneEventDuration);
eventStartIdx = eventStartIdx(stringIdx);
eventEndIdx = eventEndIdx(stringIdx);
end
eventIdx = zeros(1,max(eventEndIdx)+1);
eventIdx(eventStartIdx) = 1;
eventIdx(eventEndIdx+1) = eventIdx(eventEndIdx+1)-1;
eventIdx = find(cumsum(eventIdx));
signalActivation(tt, eventIdx) = 2;
signalActivation(tt,eventStartIdx) = +1;
signalActivation(tt,eventEndIdx) = 1;
stats(tt).startIdx = eventStartIdx;
stats(tt).endIdx = eventEndIdx;
stats(tt).duration = eventDuration;
stats(tt).eventIdx = eventIdx;
stats(tt).activation = isempty(eventIdx) = = 0;
end
videoName4Plot = strrep(videoNameInput,’_’,’\_’);
signalImFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_%s_label.tif’, videoNameInput,
signalTypeStr));
normSignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_norm.tif’, videoNameInput));
activationSignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_activ_%s_%s_%s.tif’,
videoNameInput, strPruneEvent, strFillGap, signalTypeStr));
binActivationSignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_bin_activ_%s_%s_
%s.tif’, videoNameInput, strPruneEvent, strFillGap, signalTypeStr));
signalEventsDirBox = strrep(signalEventsDir, ‘origdata’, ‘box’);
activationBoxSignalFilename = fullfile(signalEventsDirBox, sprintf(‘%s_signal_activ_%s_%s_
%s.mat’, videoNameInput, signalTypeStr, strPruneEvent, strFillGap));
activationBoxSignalFilename = strrep(activationBoxSignalFilename, ‘orig’, ‘smooth-box’);
signalActivationBox = load(activationBoxSignalFilename);
signalActivationBox = signalActivationBox.signalActivation;
signal2disk(signalArray, videoName4Plot, signalImFilename, opts);
signal2disk(signalNorm, videoName4Plot, normSignalFilename, opts);
signal2disk(signalActivation, videoName4Plot, activationSignalFilename, opts);
signal2disk(signalActivation = 0, videoName4Plot, binActivationSignalFilename, opts);
overlaySignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_overlay_%s_%s_%s.tif’,
videoNameInput, strPruneEvent, strFillGap, signalTypeStr));
overlayNormSignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_overlaynorm_%s_%s_
%s.tif’, videoNameInput, strPruneEvent, strFillGap, signalTypeStr));ell Reports 27, 3305–3314.e1–e13, June 11, 2019
signal2diskOverlay(signalArray, signalActivation = 0, videoName4Plot, overlaySignalFilename,
opts);
signal2diskOverlay(signalNorm, signalActivation = 0, videoName4Plot,
overlayNormSignalFilename, opts);
overlaySignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_overlay_%s_%s_%s_
box.tif’, videoNameInput, strPruneEvent, strFillGap, signalTypeStr));
overlayNormSignalFilename = fullfile(signalEventsDir, sprintf(‘%s_signal_overlaynorm_%s_%s_
%s_box.tif’, videoNameInput, strPruneEvent, strFillGap, signalTypeStr));
signal2diskOverlay(signalArray, signalActivationBox = 0, videoName4Plot,
overlaySignalFilename, opts);
signal2diskOverlay(signalNorm, signalActivationBox = 0, videoName4Plot,
overlayNormSignalFilename, opts);
signalFilenameMat = fullfile(signalEventsDir, sprintf(‘%s_signal_activ_%s_%s_%s.mat’,
videoNameInput, signalTypeStr, strPruneEvent, strFillGap));
save(signalFilenameMat, ‘signalActivation’);
signalStatsFilenameMat = fullfile(signalEventsDir, sprintf(‘%s_stats_%s_%s_%s.mat’,
videoNameInput, signalTypeStr, strPruneEvent, strFillGap));
save(signalStatsFilenameMat, ‘stats’);
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